‘Clear’ downtrends of major hypertension treatments

Downtrends of major hypertension treatments have become obvious.

It was observed only did 3 of 15 antihypertensive drugs have higher outpatient prescriptions in the 3^rd quarter than the record of the last year.

According to the UBIST’s data on the 25^th, the top antihypertensive drug was Boehringer Ingelheim’s Twynsta which recorded KRW 20.8 billion decreased by 6.4% compared with the last yea...